HDAC9 and melanoma: For the cases of melanoma and glioma, HDAC inhibitors have been shown to upregulate the expression of MHC-I and PD-1, and to affect PD-L1 expression via a STAT3-dependent mechanism, overall enhancing the immune response against the neoplastic cells and improving the effects of ICI therapy [22,23,24,25].